Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELVAR ELLIPTA vs SERETIDE vs FLIXOTIDE in controlled persistent asthma
NL-OMON44419Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Apr 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in persistent asthma and asthma comparing Relvar Ellipta once daily, Seretide twice daily and Flixotide twice daily (3 arms). Primary endpoint: Change from baseline in evening FEV1 at end of 24-week treatment. Started Apr 2015; status: active, not recruiting.
02
Drugs
fluticasone propionate + vilanterolsalmeterol + fluticasonefluticasone propionate
03
Conditions
persistent asthmaasthma
Beyond the preview
Go deeper on NL-OMON44419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44419.